The selective CDK4/6 inhibitor palbociclib in combination with cetuximab showed promising activity in patients with platinum-resistant or cetuximab-resistant HPV-unrelated HNSCC in a non-randomized phase 2 trial [85]. This evidence concerns the gene CDK4 and head and neck squamous cell carcinoma.